Ondansetron Doc

Ondansetron, the active ingredient in Ondansetron Doc, is a 5‑HT3 receptor antagonist presented as an oral formulation for oral use. It treats nausea and vomiting associated with chemotherapy, radiotherapy, and postoperative settings.

GNH USA supplies Ondansetron Doc as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Ondansetron works on the serotonin‑mediated pathways that trigger nausea and vomiting. It is clinically employed for the following indications: - Chemotherapy‑induced nausea and vomiting: reduces the frequency and severity of nausea and vomiting caused by cytotoxic drugs. - Radiotherapy‑induced nausea and vomiting: prevents nausea and vomiting that occur during or after radiation treatment. - Postoperative nausea and vomiting: helps to prevent nausea and vomiting following surgical procedures.

Common Side Effects: - Headache: mild to moderate headache may occur. - Constipation: reduced bowel movements are reported. - Dizziness: occasional light‑headedness. - Fatigue: feeling of tiredness. - Diarrhoea: loose stools in some patients. - Abdominal pain: mild discomfort in the stomach area.

Serious or Rare Side Effects: - QT interval prolongation: may lead to cardiac arrhythmias. - Severe allergic reaction: anaphylaxis or angioedema. - Serotonin syndrome: rare when combined with other serotonergic agents. - Cardiac arrhythmia: ventricular tachycardia in predisposed individuals. - Stevens‑Johnson syndrome: severe skin reactions. - Hepatic enzyme elevation: abnormal liver function tests.

Before prescribing Ondansetron, consider the following safety measures: - Cardiac assessment: evaluate risk of QT prolongation, especially in patients with known cardiac disease. - Concomitant QT‑prolonging drugs: avoid or monitor use with other agents that lengthen the QT interval. - Electrolyte balance: correct hypokalaemia or hypomagnesaemia prior to therapy. - Hepatic impairment: adjust dose or monitor closely in patients with liver dysfunction. - Store at ambient temperature: keep in the original packaging, protect from moisture and light.

Ondansetron may interact with several medicines. Review the following: Major Interactions (Avoid): - Apomorphine: concurrent use can cause severe hypotension and loss of consciousness. - Other QT‑prolonging agents (e.g., quinidine, haloperidol): combined effect may increase risk of arrhythmia. - Carbamazepine: induces metabolism, potentially reducing ondansetron efficacy. Moderate Interactions (Monitor Closely): - Dexamethasone: may enhance antiemetic effect; monitor for additive side effects. - Warfarin: ondansetron can increase INR; regular coagulation monitoring is advised.